The use of erythrocytes (RBC) from Presbytis cristata, P. melalophus and Macaca fascicularis for measles hemagglutination inhibition serologies is presented. These primates can provide a ready supply of RBC for diagnostic reagent use in areas of the world where the African green monkey or rhesus macaque are not available. Individuals of each species are useful but must be screened for hemagglutination ability of their erythrocytes. The animal can then be chosen that has erythrocytes which best agglutinate with the antigen being used.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Selection of DNA aptamer for label-free electrochemical aptasensor for the detection of rubella virus.
Talanta
October 2024
Department of Chemistry, Alfaisal University, Al Zahrawi Street, Al Maather, Al Takhassusi Road, Riyadh, 11533, Saudi Arabia. Electronic address:
The Rubella virus (RUBV) is a highly contagious pathogen classified within the rubivirus genus, primarily infecting humans and transmitted via airborne routes. RUBV infection generally manifests as a mild illness reminiscent of measles. However, when affecting pregnant women, it can lead to a severe condition known as congenital rubella syndrome (CRS).
View Article and Find Full Text PDFExcessive daytime sleepiness is associated with impaired antibody response to influenza vaccination in older male adults.
Front Cell Infect Microbiol
December 2023
Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN, United States.
Background: The reduced effectiveness of standard-dose influenza vaccines in persons ≥65 years of age led to the preferential recommendation to use high-dose (HDFlu) or MF59-adjuvanted (MF59Flu) vaccines for this age group. Sleep is an important modulator of immune responses to vaccines and poor sleep health is common in older adults. However, potential effects of poor sleep health on immune responses to influenza vaccination in older adults remain largely unknown.
View Article and Find Full Text PDFA protective measles virus-derived vaccine inducing long-lasting immune responses against influenza A virus H7N9.
NPJ Vaccines
March 2023
Section 4/3: Product Testing of IVMPs, Paul-Ehrlich-Institut, Paul-Ehrlich-Straße 51-59, 63225, Langen, Germany.
A novel Influenza A virus (subtype H7N9) emerged in spring 2013 and caused considerable mortality in zoonotically infected patients. To be prepared for potential pandemics, broadly effective and safe vaccines are crucial. Recombinant measles virus (MeV) encoding antigens of foreign pathogens constitutes a promising vector platform to generate novel vaccines.
View Article and Find Full Text PDFT Cell Transcriptional Signatures of Influenza A/H3N2 Antibody Response to High Dose Influenza and Adjuvanted Influenza Vaccine in Older Adults.
Viruses
December 2022
Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA.
Older adults experience declining influenza vaccine-induced immunity and are at higher risk of influenza and its complications. For this reason, high dose (e.g.
View Article and Find Full Text PDFAnalysis of Viral and Host Factors on Immunogenicity of 2018, 2019, and 2020 Southern Hemisphere Seasonal Trivalent Inactivated Influenza Vaccine in Adults in Brazil.
Viruses
July 2022
Laboratory of Respiratory Viruses and Measles, National Influenza Center (NIC)/World Health Organization (WHO), Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro 21040-900, Brazil.
Annual vaccination against influenza is the best tool to prevent deaths and hospitalizations. Regular updates of trivalent inactivated influenza vaccines (TIV) are necessary due to high mutation rates in influenza viruses. TIV effectiveness is affected by antigenic mismatches, age, previous immunity, and other host factors.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!